Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 0859 • ACR Convergence 2020
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Ed Vital¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Richard Furie⁶, Thomas Schindler⁷, Jay Garg⁸, Matthew Cascino⁸, Zahir Amoura⁹, Andrea Doria¹⁰, Cary Looney⁸ and Dario Roccatello¹¹, ¹University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁸Genentech, Inc., South San Francisco, CA, ⁹Hôpital Pitié-Salpêtrière, Paris, ¹⁰University of Padua, Padua, Italy, ¹¹S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
Abstract Number: 0988 • ACR Convergence 2020
Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis
Richard Furie¹, Gustavo Aroca², Analia Alvarez³, Hilda Fragoso-Loyo⁴, Elizabeth Zuta Santillan⁵, Brad Rovin⁶, Paul Brunetta⁷, Thomas Schindler⁸, Imran Hassan⁹, Matthew Cascino¹⁰, Jay Garg¹⁰ and Ana Malvar¹¹, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, ³CEMIC, Buenos Aires, Argentina, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Instituto de Ginecología y Reproducción, Lima, Peru, ⁶The Ohio State University, Columbus, ⁷Genentech, Inc., South San Francisco, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Hoffmann-La Roche Ltd, Mississauga, Canada, ¹⁰Genentech, Inc., South San Francisco, CA, ¹¹Organizacion Medica de Investigacion, Buenos Aires, Argentina
Background/Purpose: NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through…
Abstract Number: 1836 • ACR Convergence 2020
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Zahir Amoura¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Dario Roccatello⁶, Richard Furie⁷, Thomas Schindler⁸, Jay Garg⁹, Matthew Cascino⁹, Brad Rovin¹⁰ and Andrea Doria¹¹, ¹Hôpital Pitié-Salpêtrière, Paris, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶S Giovanni Hospital, Univ of Turin, Turin, Italy, ⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰The Ohio State University, Columbus, ¹¹University of Padua, Padua, Italy
Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
Abstract Number: 939 • 2019 ACR/ARP Annual Meeting
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis
Richard Furie¹, Gustavo Aroca ², Analía Alvarez ³, Hilda Fragoso-Loyo ⁴, Elizabeth Zuta Santillán ⁵, Brad Rovin ⁶, Thomas Schindler ⁷, Imran Hassan ⁸, Matthew Cascino ⁹, Jay P. Garg ¹⁰ and Ana Malvar ¹¹, ¹Northwell Health, Great Neck, NY, ²Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, ³CEMIC, Buenos Aires, Argentina, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, ⁵Instituto de Ginecología y Reproducción, Lima, Peru, ⁶The Ohio State University Medical Center, Columbus, OH, ⁷F. Hoffmann-La Roche AG, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., San Fransisco, CA, ¹⁰Genentech, Inc., South San Francisco, CA, ¹¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina
Background/Purpose: Randomized trials in lupus nephritis (LN) of type I anti-CD20 monoclonal antibodies failed to demonstrate superiority over standard of care alone. NOBILITY (NCT02550652) is…
Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy¹, Christian Klein², David A. Isenberg³, Geraldine Cambridge⁴, Martin Glennie⁵, Mark Cragg⁶ and Maria J. Leandro¹, ¹Rheumatology, University College London, London, United Kingdom, ²Roche Pharmaceutical Research & Early Development Oncology Discovery & Translational Area, Roche Glycart AG, Schlieren, Switzerland, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Rheumatology, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ⁵Antibody and Vaccine group, Southampton University, Southampton, United Kingdom, ⁶Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »